Skip to main content

Table 4 Ability of CEA and CYFRA 21-1 to predict DCR (CR + PR + SD) in a multivariate analysis

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  Odds ratio 95% CI p-value
Gender
Male 1.0   0.13
Female 1.85 (0.8–4.1)
Age
 ≤ 70 1.0   0.48
 > 70 1.31 (0.6–2.8)
CEA reduction ≥ 20%
No 1.0   0.32
Yes 1.58 (0.6–3.9)
CYFRA 21-1 reduction ≥ 20%
No 1.0   0.002
Yes 4.36 (1.7–11.3)